6 news items
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
ALGS
5 Jun 24
and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
ALGS
22 May 24
materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
ALGS
25 Apr 24
risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
ALGS
3 Apr 24
are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially
btf2 693vh5xlfjsuj66gpt12m5rff76repor1tphi21
ALGS
27 Mar 24
that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward
- Prev
- 1
- Next